Molecular Assemblies
TriLink BioTechnologies specializes in nucleic acid technologies, including mRNA synthesis, capping, and DNA synthesis, with a focus on advancing RNA vaccines and therapeutics. They offer innovative solutions such as CleanCap technology, enzymatic DNA synthesis, and custom oligonucleotides to support research, development, and manufacturing in biotech and pharmaceutical sectors.
Industries
Nr. of Employees
small (1-50)
Molecular Assemblies
1453292893/h/j_IwKVzP_lfeO0IcVsPw-js8GI4yhgi1i1NGIeCYcAs
Patents
Products
Catalog research mRNAs
Off-the-shelf research mRNA constructs and standards in defined sizes suitable for discovery and early-stage work.
Cap analog reagents for co-transcriptional capping
Cap analog reagents designed for co-transcriptional incorporation to generate Cap1 structures and improve mRNA translation efficiency.
Modified nucleotide triphosphates (NTPs)
Modified NTPs such as methylated and methoxyuridine triphosphates supplied for incorporation into in vitro–transcribed mRNA to modulate immunogenicity and translation.
Long single-stranded DNA oligonucleotides (enzymatic synthesis)
Long ssDNA oligonucleotides produced by an enzymatic synthesis platform, reported to achieve high per-step incorporation efficiency and to simplify downstream purification.
Catalog research mRNAs
Off-the-shelf research mRNA constructs and standards in defined sizes suitable for discovery and early-stage work.
Cap analog reagents for co-transcriptional capping
Cap analog reagents designed for co-transcriptional incorporation to generate Cap1 structures and improve mRNA translation efficiency.
Modified nucleotide triphosphates (NTPs)
Modified NTPs such as methylated and methoxyuridine triphosphates supplied for incorporation into in vitro–transcribed mRNA to modulate immunogenicity and translation.
Long single-stranded DNA oligonucleotides (enzymatic synthesis)
Long ssDNA oligonucleotides produced by an enzymatic synthesis platform, reported to achieve high per-step incorporation efficiency and to simplify downstream purification.
Services
Contract manufacturing and GMP production support for mRNA and plasmid DNA products.
Supply of long single-stranded oligonucleotides produced via enzymatic synthesis with in-process purification to reduce downstream purification steps.
Commercial availability of modified nucleotide triphosphates and cap analog reagents for mRNA synthesis and research.
Consultation services and assessment tools to estimate time and cost impacts of different mRNA manufacturing choices and to support process development decisions.
Contract manufacturing and GMP production support for mRNA and plasmid DNA products.
Supply of long single-stranded oligonucleotides produced via enzymatic synthesis with in-process purification to reduce downstream purification steps.
Commercial availability of modified nucleotide triphosphates and cap analog reagents for mRNA synthesis and research.
Consultation services and assessment tools to estimate time and cost impacts of different mRNA manufacturing choices and to support process development decisions.
Expertise Areas
- mRNA process development and manufacturing
- mRNA capping strategies and cap analogs
- Enzymatic synthesis of long oligonucleotides
- Modified nucleotide chemistry and NTP supply
Key Technologies
- In vitro transcription (IVT) optimization
- Co-transcriptional capping (cap analogs, Cap1 generation)
- Enzymatic DNA synthesis (fully enzymatic synthesis)
- Modified nucleotide triphosphates (e.g., N1-methylpseudouridine)
News & Updates
Seminar Series in Paris
Building momentum in mRNA from discovery through clinical trials, featuring industry leaders and scientists.
Seminar Series in Boston
Exploring the future of RNA vaccines and therapeutics, with expert speakers and networking opportunities.
Seminar Series in Philadelphia
Advancing research in mRNA, RNA modifications, and vaccine development.
Seminar Series in Heidelberg
Pioneering versatile LNP production processes for mRNA vaccines and therapeutics.
Seminar Series in Basel
Impact of cap structures on mRNA performance and vaccine innovations.
Seminar Series in Durham
The future of genomic medicine and RNA technology.
Seminar Series in Paris
Building momentum in mRNA from discovery through clinical trials, featuring industry leaders and scientists.
Seminar Series in Boston
Exploring the future of RNA vaccines and therapeutics, with expert speakers and networking opportunities.
Seminar Series in Philadelphia
Advancing research in mRNA, RNA modifications, and vaccine development.
Seminar Series in Heidelberg
Pioneering versatile LNP production processes for mRNA vaccines and therapeutics.
Seminar Series in Basel
Impact of cap structures on mRNA performance and vaccine innovations.
Seminar Series in Durham
The future of genomic medicine and RNA technology.